Robeco Schweiz’s Myriad Genetics MYGN Stock Holding History

Robeco Schweiz’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,300	Closed	-$436K	–	162
2019 Q2	$436K	Buy	16,300 +1,180	+8%	+$33.3K	0.02%	135
2019 Q1	$502K	Buy	15,120 +2,820	+23%	+$85.8K	0.02%	137
2018 Q4	$352K	Buy	12,300 +9,300	+310%	+$335K	0.02%	138
2018 Q3	$139K	Sell	3,000 -1,193	-28%	-$53K	0.01%	160
2018 Q2	$156K	Buy	4,193 +1,193	+40%	+$40.3K	0.01%	157
2018 Q1	$89K	Hold	3,000	–	–	﹤0.01%	165
2017 Q4	$104K	Hold	3,000	–	–	0.01%	163
2017 Q3	$109K	Hold	3,000	–	–	0.01%	168
2017 Q2	$77K	Hold	3,000	–	–	0.01%	177
2017 Q1	$57K	Hold	3,000	–	–	﹤0.01%	183
2016 Q4	$50K	Sell	3,000 -47,934	-94%	-$867K	﹤0.01%	188
2016 Q3	$1.05M	Buy	+50,934	New	+$1.29M	0.09%	128

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Robeco Schweiz's MYGN Position: Q3 2019 in Review

Robeco Schweiz sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 16,300 shares — an estimated $436K sold.

Robeco Schweiz first reported a position in MYGN in Q3 2016 and held it in 12 quarters. The position peaked at $1.05M in Q3 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Robeco Schweiz reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Robeco Schweiz sold 16,300 Myriad Genetics shares in Q3 2019, an estimated $436K.
Robeco Schweiz first reported a position in Myriad Genetics in Q3 2016 and held it in 12 quarters.
Robeco Schweiz's Myriad Genetics position peaked at $1.05M in Q3 2016.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Robeco Schweiz's 13F filing for Q3 2019, filed 18 Oct 2019.